Abstract:Through genetic and epigenetic alterations, cancer cells present the immune system with a diversity of antigens or neoantigens, which the organism must distinguish from self. The immune system responds to neoantigens by activating naïve T cells, which mount an anticancer cytotoxic response. T cell activation begins when the T cell receptor (TCR) interacts with the antigen, which is displayed by the major histocompatibility complex (MHC) on antigen-presenting cells (APCs). Subsequently, accessory stimulatory or inhibitory molecules transduce a secondary signal in concert with the TCR/antigen mediated stimulus. These molecules serve to modulate the activation signal’s strength at the immune synapse. Therefore, the activation signal’s optimum amplitude is maintained by a balance between the costimulatory and inhibitory signals. This system comprises the so-called immune checkpoints such as the programmed cell death (PD-1) and Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and is crucial for the maintenance of self-tolerance. Cancers often evade the intrinsic anti-tumor activity present in normal physiology primarily by the downregulation of T cell activation. The blockade of the immune checkpoint inhibitors using specific monoclonal antibodies has emerged as a potentially powerful anticancer therapy strategy. Several drugs have been approved mainly for solid tumors. However, it has emerged that there are innate and acquired mechanisms by which resistance is developed against these therapies. Some of these are tumor-intrinsic mechanisms, while others are tumor-extrinsic whereby the microenvironment may have innate or acquired resistance to checkpoint inhibitors. This review article will examine mechanisms by which resistance is mounted against immune checkpoint inhibitors focussing on anti-CTL4-A and anti-PD-1/PD-Ll since drugs targeting these checkpoints are the most developed.

Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy

Targeting Tumor Physical Microenvironment for Improved Radiotherapy

Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance

Advances in targeting tumor microenvironment for immunotherapy

Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Biophysical and biochemical aspects of immune cell–tumor microenvironment interactions

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing

Role of tumor microenvironment in cancer progression and therapeutic strategy

Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies

Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy

The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways

Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications

Biomaterials tools to modulate the tumour microenvironment in immunotherapy

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies

Tumor Metabolic Crosstalk and Immunotherapy

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

The tumor microenvironment: a key player in multidrug resistance in cancer